CD36 and metabolic dysfunction-associated steatotic liver disease: CD36 has been previously evaluated as a therapeutic target in diseases other than cancer, such as atherosclerosis, non-alcoholic fatty liver disease, and diabetes [85,87,88,106,107,108].